加拿大Vasogen Inc www.vasogen.com
Vasogen Inc. (多倫多，Toronto) 是以心血管疾病或神經(jīng)疾病所引發(fā)的慢性發(fā)炎作為治療標靶，來進行新藥物科技研發(fā)的公司，宣布Christopher J. Waddick被擢升為營運長，Paul J. Van Damme擔任財務(wù)部門副總裁及財務(wù)長，Jacqueline H.R. Le Saux擔任公司及法律業(yè)務(wù)部門副總裁
We are a biotechnology company that is focused on the research and commercial development of therapies designed to target the destructive inflammatory processes associated with the development and progression of cardiovascular and neuro-inflammatory disorders. Our most advanced product, the Celacade™ System, is designed to activate the immune response to apoptosis – an important physiological process that regulates inflammation. We are also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. Our two initial product candidates, VP015 and VP025, are biological ligands designed to exploit specific physiological anti-inflammatory responses of the immune system. The effects of these drugs have been shown to cross the blood-brain barrier and improve outcomes in a broad range of preclinical models, demonstrating their disease-modifying potential.